-
Gastric acid suppression medications increase risk for recurrence of Clostridium difficile infection
Share this:
ROCHESTER, Minn. – Researchers at Mayo Clinic have found patients who use gastric suppression medications are at a higher risk for recurrent Clostridium difficile (C-diff) infection. C-diff is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. The study is published in JAMA Internal Medicine.
"In our study, we found that use of gastric acid suppression medications are associated with a statistically significant increased risk of development of recurrent C-diff in patients with a prior episode of C-diff," says Sahil Khanna, M.B.B.S., a gastroenterologist at Mayo Clinic and senior author of the study.
Dr. Khanna says gastric suppression medications studied include proton pump inhibitors, such as omeprazole, and histamine 2 blockers, such as ranitidine, which are commonly prescribed and consumed over-the-counter medications for gastroesophageal reflux disease, peptic ulcer disease or dyspepsia.
In a systematic review and meta-analysis of 16 studies with 7,703 patients with C-diff, 1,525 developed recurrent C-diff. The rate of recurrent C-diff in patients with gastric suppression was 22.1 percent, compared to 17.3 percent in patients without gastric acid suppression.
Dr. Khanna urges caution in interpreting these findings due to variables not considered in the study, such as the underlying reason why the gastric acid suppressant was needed. However, he says the findings suggest that patients with C-diff who receive gastric acid suppressants may be at increased risk of C-diff recurrence. "It may be reasonable to re-evaluate the need for these medications in patients with C-diff," Dr. Khanna says.
Co-authors are:
- Raseen Tariq, M.B.B.S., Mayo Clinic
- Darrel Pardi, M.D., Mayo Clinic
- Siddharth Singh, M.B.B.S., University of California San Diego
- Arjun Gupta, M.B.B.S., University of Texas South Western
###
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit mayoclinic.org/about-mayo-clinic or newsnetwork.mayoclinic.org.
MEDIA CONTACT
Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu
Share this:
Related articles
At Mayo Clinic Laboratories, where teamwork powers innovation, a cross-laboratory collaboration has enabled implementation of a cutting-edge, gold standard test for a life-threatening condition known ...
National Wear Red Day is an annual event held each first Friday of February, dedicated to raising awareness about heart disease in women. It's the ...
Congenital heart disease is the most commonly diagnosed disorder in newborns worldwide. While babies born with this condition are living longer and healthier lives, some ...